{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "CAD", "firstTradeDateMilliseconds": 1517212800000, "priceHint": 4, "bookValue": -0.223, "fiftyDayAverage": 0.1675, "fiftyDayAverageChange": -0.022500008, "fiftyDayAverageChangePercent": -0.13432841, "twoHundredDayAverage": 0.1675, "twoHundredDayAverageChange": -0.022500008, "twoHundredDayAverageChangePercent": -0.13432841, "priceToBook": -0.6502242, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "regularMarketChangePercent": -14.705885, "regularMarketPrice": 0.145, "marketState": "POSTPOST", "exchange": "LSE", "shortName": "RESVERLOGIX CORP RESVERLOGIX OR", "longName": "Resverlogix Corp.", "messageBoardId": "finmb_3103092", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "regularMarketChange": -0.025000006, "regularMarketTime": 1683129301, "regularMarketDayHigh": 0.0, "regularMarketDayRange": "0.0 - 0.0", "regularMarketDayLow": 0.0, "regularMarketVolume": 120000, "regularMarketPreviousClose": 0.17, "fullExchangeName": "LSE", "financialCurrency": "USD", "regularMarketOpen": 0.0, "averageDailyVolume3Month": 26669, "averageDailyVolume10Day": 20251, "fiftyTwoWeekLowChange": 0.145, "fiftyTwoWeekRange": "0.0 - 0.25", "fiftyTwoWeekHighChange": -0.105000004, "fiftyTwoWeekHighChangePercent": -0.42000002, "fiftyTwoWeekLow": 0.0, "fiftyTwoWeekHigh": 0.25, "earningsTimestamp": 1668114000, "earningsTimestampStart": 1668114000, "earningsTimestampEnd": 1668114000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "0VF9.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "4820 Richard Road SW", "address2": "Suite 300", "city": "Calgary", "state": "AB", "zip": "T3E 6L1", "country": "Canada", "phone": "403-254-9252", "fax": "403-256-8495", "website": "https://www.resverlogix.com", "industry": "", "sector": "", "longBusinessSummary": "Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.", "fullTimeEmployees": 19, "companyOfficers": [{"maxAge": 1, "name": "Mr. Donald J. McCaffrey", "title": "Co-Founder, Chairman, Pres, CEO & Sec.", "fiscalYear": 2021, "totalPay": {"raw": 505200, "fmt": "505.2k", "longFmt": "505,200"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV", "title": "Chief Financial Officer", "fiscalYear": 2021, "totalPay": {"raw": 281800, "fmt": "281.8k", "longFmt": "281,800"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ewelina  Kulikowski Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2021, "totalPay": {"raw": 250000, "fmt": "250k", "longFmt": "250,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jan O. Johansson M.D., Ph.D.", "title": "Sr. VP of Medical Affairs", "fiscalYear": 2021, "totalPay": {"raw": 300785, "fmt": "300.79k", "longFmt": "300,785"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Michael  Sweeney M.D.", "age": 61, "title": "Sr. VP of Clinical Devel.", "yearBorn": 1961, "fiscalYear": 2021, "totalPay": {"raw": 492911, "fmt": "492.91k", "longFmt": "492,911"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Sarah  Zapotichny", "title": "Director of Investor Relations & Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}